Portola Pharmaceuticals (NASDAQ:PTLA) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Thursday.

A number of other equities analysts have also recently commented on PTLA. Oppenheimer set a $80.00 target price on Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. Credit Suisse Group upgraded Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 target price for the company in a report on Wednesday, August 23rd. Goldman Sachs Group began coverage on Portola Pharmaceuticals in a report on Friday, December 1st. They issued a “buy” rating and a $75.00 target price for the company. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $81.00 target price (up previously from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $71.15.

Portola Pharmaceuticals (PTLA) opened at $54.73 on Thursday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31. Portola Pharmaceuticals has a 1-year low of $18.63 and a 1-year high of $67.10.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.49) by $0.08. The firm had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The company’s quarterly revenue was down 58.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.64) EPS. research analysts predict that Portola Pharmaceuticals will post -4.94 EPS for the current fiscal year.

In related news, Director Henry Ward Wolff sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Kornitzer Capital Management Inc. KS lifted its stake in shares of Portola Pharmaceuticals by 38.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock worth $39,324,000 after acquiring an additional 202,925 shares during the last quarter. Sivik Global Healthcare LLC bought a new stake in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $1,685,000. State Street Corp lifted its stake in shares of Portola Pharmaceuticals by 5.3% during the 2nd quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock worth $117,164,000 after acquiring an additional 105,207 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $1,047,000. Finally, Numeric Investors LLC bought a new stake in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $753,000. 87.25% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/portola-pharmaceuticals-ptla-lifted-to-sell-at-bidaskclub/1775437.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.